How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
EP 113: Harnessing human genetics to discover co-evolved small molecule medicines with Dr. Jason Park, CEO of Empress Therapeutics
MP3•Episode home
Manage episode 388131882 series 2631947
Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of The Genetics Podcast, we welcome Dr. Jason, founder and CEO of Empress Therapeutics, a Flagship Pioneering company. Join us as we discuss how human genetics can identify small molecules with therapeutic potential that are already created by our bodies, paving the way for faster discovery of new medicines.
Summary:
Summary:
0:00 Intro
1:20 Understanding parts of the genome that create and modify small molecules
5:50 The central dogma of molecular biology
8:50 Jason’s background founding biotech companies
11:45 Flagship pioneering: combining scientific discovery and engineering innovations
13:10 The foundation of Empress Therapeutics: biological insight, data, and artificial intelligence
19:30 Learning from disease states and following the thread from DNA to small molecule
22:20 Differences in genetic chemistry across people and case studies
25:30 Potential biological limitations of the small molecule approach
28:00 Using human genetics and synthetic biology to create impactful medicines
32:00 What happens in ‘stealth mode’
36:00 The limiting reactant of scaling small molecule therapies to a wider platform
38:20 The role of the metagenome
40:00 Lessons learned from founding multiple companies
42:20 Origins of the name Empress Therapeutics
43:40 Closing remarks
167 episodes
MP3•Episode home
Manage episode 388131882 series 2631947
Content provided by Sano Genetics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sano Genetics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of The Genetics Podcast, we welcome Dr. Jason, founder and CEO of Empress Therapeutics, a Flagship Pioneering company. Join us as we discuss how human genetics can identify small molecules with therapeutic potential that are already created by our bodies, paving the way for faster discovery of new medicines.
Summary:
Summary:
0:00 Intro
1:20 Understanding parts of the genome that create and modify small molecules
5:50 The central dogma of molecular biology
8:50 Jason’s background founding biotech companies
11:45 Flagship pioneering: combining scientific discovery and engineering innovations
13:10 The foundation of Empress Therapeutics: biological insight, data, and artificial intelligence
19:30 Learning from disease states and following the thread from DNA to small molecule
22:20 Differences in genetic chemistry across people and case studies
25:30 Potential biological limitations of the small molecule approach
28:00 Using human genetics and synthetic biology to create impactful medicines
32:00 What happens in ‘stealth mode’
36:00 The limiting reactant of scaling small molecule therapies to a wider platform
38:20 The role of the metagenome
40:00 Lessons learned from founding multiple companies
42:20 Origins of the name Empress Therapeutics
43:40 Closing remarks
167 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.